Journal article

Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine

Daniel Cowley, Daniel Pavlic, Nada Bogdanovic-Sakran, Karen Boniface, Carl D Kirkwood, Julie E Bines

HUMAN VACCINES & IMMUNOTHERAPEUTICS | TAYLOR & FRANCIS INC | Published : 2018

Grants

Awarded by Bill and Melinda Gates Foundation


Awarded by Australian National Health and Medical Research Council


Awarded by New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative


Funding Acknowledgements

This study was funded by an investigator driven grant from the Bill and Melinda Gates Foundation (OPP1127967). The Phase IIa clinical trial of RV3-BB was supported by the Australian National Health and Medical Research Council through a project grant (ID491239) and the New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative (08_T02). This research was also supported by the Victorian Government's Operational Infrastructure Support Program.